ROSWELL PARK CANCER INSTITUTE CORP
TLR5 enhancement of liver-directed radiotherapy plus immune checkpoint blockade against irradiated liver metastasis and abscopal tumors
TLR5 enhancement of liver-directed radiotherapy plus immune checkpoint blockade against irradiated liver metastasis and abscopal tumors is a funding opportunity from ROSWELL PARK CANCER INSTITUTE CORP, up to 698501, closing May 31, 2028.
May 31, 2028
(670d left)Overview
The liver is a frequent site of metastasis for several cancers and when this occurs, it is associated with poor response to immunotherapy. Liver-directed radiotherapy (RT) is a non-traditional immune modulating therapy that improves immune checkpoint blockade (ICB, αPD-1 or αPD-1/αCTLA-4) mediated control of liver…